The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comprehensive characterization of ERBB2 genomic alterations inlung cancer.
 
Talal El Zarif
No Relationships to Disclose
 
Paul Stockhammer
No Relationships to Disclose
 
Jacob Schillo
No Relationships to Disclose
 
Sarah B. Goldberg
Honoraria - Amgen
Consulting or Advisory Role - AstraZeneca/MedImmune; Daiichi Sankyo; Genzyme; Janssen; Merck; Regeneron; Summit Therapeutics
Research Funding - Amgen (Inst); AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Mirati Therapeutics; ORIC Pharmaceuticals (Inst); Pfizer (Inst); Spectrum Pharmaceuticals (Inst)
 
Katerina A. Politi
Stock and Other Ownership Interests - Reveal Therapeutics, Inc
Consulting or Advisory Role - AstraZeneca; Janssen; Pfizer; Pfizer
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); D2G Oncology (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - I am a co-inventor on a patent licensed by MSKCC to Molecular MD for T790M testing
Travel, Accommodations, Expenses - AstraZeneca; Roche/Genentech
(OPTIONAL) Uncompensated Relationships - Lung Cancer Research Foundation
 
Michael J Grant
Honoraria - Daiichi Sankyo/Astra Zeneca
Consulting or Advisory Role - Regeneron
Research Funding - Adela (Inst)